A Phase 1 Bioequivalence Study to Assess the Pharmacokinetics, Safety and Tolerability of Guselkumab After a Single‐Dose Administration via Two Subcutaneous Injection Devices in Healthy Volunteers
Clinical Pharmacology in Drug Development · 2026
DOI: 10.1002/cpdd.70007 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2026. Verfasst von Angela Jeong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology and Pharmacometrics, Johnson & Johnson, Spring House, PA, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
Guselkumab is approved for the treatment of psoriasis, psoriatic arthritis, as well as ulcerative colitis and Crohn's disease. Two delivery devices for subcutaneous (SC) injection previously had been approved for the administration of 100 mg guselkumab. This study was designed to demonstrate the bioequivalence and tolerability of guselkumab following a single‐dose SC administration of 100 mg guselkumab using a 1 mL prefilled syringe (PFS) assembled with an Ypsomate autoinjector (i.e., 1 mL PFS‐Y, Test device) as compared to the approved 1 mL PFS assembled with the UltraSafe Plus needle safety guard (i.e., 1 mL PFS‐U, Reference device). Mean serum guselkumab concentration–time profiles were nearly superimposable for both devices following a single SC injection. The geometric mean ratios and the corresponding 90% confidence interval [CI] for C max and AUC inf were 102.28% (94.85%–110.30%) and 102.10% (95.19%–109.51%), respectively. There were no significant differences in the incidence of treatment‐emergent adverse events between the two treatment groups, and the incidence of treatment‐emergent anti‐drug antibodies was low and comparable between the two groups. Overall, these results suggest that the pharmacokinetics, safety/tolerability, and immunogenicity of guselkumab are comparable when administered via the 1 mL PFS‐Y and 1 mL PFS‐U.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology and Pharmacometrics, Johnson & Johnson, Spring House, PA, USA.
- Immunology Clinical Development, Johnson & Johnson, Spring House, PA, USA.
- Preclinical Sciences & Translational Safety, Johnson & Johnson, Spring House, PA, USA.
- Statistics & Decision Science, Johnson & Johnson, Titusville, NJ, USA.
- Clinical Pharmacology and Pharmacometrics, Johnson & Johnson, Beerse, Belgium.
Zitieren
APA
Jeong, A., Weisel, K., Dimitrova, D., Donnelly, B., Wang, D., Vermeulen, A., & Xu, Z. (2026). A Phase 1 Bioequivalence Study to Assess the Pharmacokinetics, Safety and Tolerability of Guselkumab After a Single‐Dose Administration via Two Subcutaneous Injection Devices in Healthy Volunteers. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.70007
Vancouver
Jeong A, Weisel K, Dimitrova D, Donnelly B, Wang D, Vermeulen A, et al. A Phase 1 Bioequivalence Study to Assess the Pharmacokinetics, Safety and Tolerability of Guselkumab After a Single‐Dose Administration via Two Subcutaneous Injection Devices in Healthy Volunteers. Clinical Pharmacology in Drug Development. 2026. doi:10.1002/cpdd.70007
BibTeX
@article{Jeong2026,
author = {Jeong, Angela and Weisel, Kathleen and Dimitrova, Dessislava and Donnelly, Brianna and Wang, Daniel and Vermeulen, An and Xu, Zhenhua},
title = {A Phase 1 Bioequivalence Study to Assess the Pharmacokinetics, Safety and Tolerability of Guselkumab After a Single‐Dose Administration via Two Subcutaneous Injection Devices in Healthy Volunteers},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
doi = {10.1002/cpdd.70007}
}
EUVIMED